Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1341-1360 of 3,900 trials

Ovarian Cancer: SALVOVAR Trial on Chemotherapy Regimens

We are studying whether a new weekly chemotherapy schedule improves outcomes for patients with poor prognostic ovarian cancer compared to the standard treatment. This trial aims to see if it helps with surgery success and overall survival.

Advanced Ovarian and Fallopian Tube Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Liver Transplant: Regulatory T Cell Therapy

We are studying a new treatment using regulatory T cells for liver transplant recipients to see if it is safe and allows them to stop taking tacrolimus. We also want to learn how it affects graft function and patients' quality of life.

Liver TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Advanced Non-Small Cell Lung Cancer: Rilvegostomig Study

We are testing a new treatment called rilvegostomig in adults with advanced or metastatic non-small cell lung cancer. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Advanced Lung CancerSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Meniscal Loss: Spongioflex® Allografts Study

We are investigating whether sterile allogeneic spongioflex® allografts can improve knee function in patients with incomplete meniscal loss. The study will also assess safety and patient satisfaction over several years.

Meniscus Tear>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOrthopedics and Traumatology

Advanced Solid Tumors: AZD0901 Treatment Study

We are investigating the safety and effectiveness of AZD0901, alone or with other cancer drugs, for patients with advanced solid tumors expressing Claudin 18.2. This study aims to understand how well this treatment may work and its potential side effects.

Gastric CancerGastroesophageal Junction CancerPancreatic Ductal AdenocarcinomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Gastric Cancer: AZD0901 Treatment Study

We are studying how well AZD0901 works and its safety compared to standard treatments for adults with advanced gastric or gastroesophageal junction cancer that has high levels of a protein called CLDN18.2.

Advanced Gastric CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Recurrent Glioblastoma: Ipilimumab and Nivolumab Treatment

We are testing a new combination of two immunotherapy drugs for patients with recurrent glioblastoma. The goal is to see if this approach improves treatment outcomes compared to standard options.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Dextroamphetamine for Amphetamine Dependence: A Clinical Trial

We are studying whether daily prescribed dextroamphetamine can help reduce illicit amphetamine use in adults with amphetamine and opioid dependencies. The trial also looks at its effects on mental health, physical health, and overall quality of life.

Comorbid Dependencies to Amphetamines and Opioids6-12 monthsEfficacy phase (II)Standard MedicinesPsychiatry

Heart Function Study: Dobutamine in ATTRwt Patients

We are investigating how different doses of dobutamine affect heart performance in patients with wild-type transthyretin amyloid cardiomyopathy. The study also looks at the safety of this treatment.

Wild-type Transthyretin Amyloid Cardiomyopathy1-2 yearsEfficacy phase (II)Standard MedicinesCardiologyInternal Medicine

Urothelial Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with advanced urothelial cancer that cannot be removed by surgery. The study aims to see how effective and safe this treatment is compared to existing options.

Urothelial Cancer of the Renal Pelvis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOncologyUrology

Treatment-Resistant Depression: P-glycoprotein Study

We are investigating how a protein may affect people with treatment-resistant depression using advanced imaging. This study compares P-glycoprotein activity in those who do not respond to treatment with those who do.

Depression1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Ulcerative Colitis: GS-1427 Study

We are testing a new medication, GS-1427, for adults with moderately to severely active ulcerative colitis. The study aims to see if it can improve symptoms and achieve remission compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

NBI-1076986: Safety and Effects in Healthy Adults

We are studying a new medication to see how safe it is and how the body reacts to it in healthy adults. This research helps us understand its potential for future use in patients.

Movement Disorders>2 yearsSafety phase (I)Neurology

Liver Tumors: Indocyanine Green for Better Detection

We are testing whether a dye can help surgeons find liver tumors more easily during surgery. This study aims to improve surgical outcomes and understand how the dye behaves in the liver.

Resectable Malignant Liver Tumor>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHepatologyOncology

Cushing’s Syndrome: Fluasterone Buccal Tablet

We are studying whether fluasterone can help control high blood sugar in adults with Cushing’s syndrome. The trial will also look at its safety and effects on weight and cholesterol levels.

Cushing's Syndrome≤3 monthsEfficacy phase (II)Investigational MedicinesDiabetologyEndocrinologyInternal Medicine

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart vs. IVIg

We are studying a new treatment called riliprubart to see if it works better than the standard IVIg therapy for people with chronic inflammatory demyelinating polyneuropathy. The trial will evaluate its effects on disability, fatigue, and overall quality of life.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesInternal MedicineNeurology

Non-Small Cell Lung Cancer: Furmonertinib Study

We are evaluating the safety and effectiveness of Furmonertinib for patients with non-small cell lung cancer who have specific EGFR or HER2 mutations. This study aims to see how well the drug works in treating this type of cancer.

Non-Small Cell Lung Cancer (NSCLC)Safety phase (I)OncologyPulmonology

Relapsed/Refractory T-Cell Leukemia: CD7 CAR T-Cell Therapy

We are testing a new type of T-cell therapy for children and young adults with relapsed or refractory T-cell leukemia or lymphoma. The study aims to find a safe dose and see how well it works.

T-cell Acute Lymphoblastic Leukemia/Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Metastatic Pancreatic Adenocarcinoma: TTX-030 and Chemotherapy

We are studying if adding TTX-030 and possibly budigalimab to standard chemotherapy helps patients with untreated metastatic pancreatic cancer. This trial aims to evaluate the effectiveness and safety of these combinations.

Metastatic Pancreatic Cancer1-2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Lung Cancer: ABP 234 vs. Keytruda

We are evaluating a new treatment for early-stage non-squamous non-small cell lung cancer to see how it compares to Keytruda after surgery and chemotherapy. This study aims to understand if the new drug works similarly in the body.

Early-stage Non-squamous Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)OncologyPulmonology